FATE FY2025 EPS Forecast Increased by Cantor Fitzgerald

Fate Therapeutics, Inc. (NASDAQ:FATE) – Investment analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for Fate Therapeutics in a research note issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company will earn ($1.20) per share for the year, up from their previous forecast of ($1.67). The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share.

FATE has been the subject of several other reports. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a report on Thursday, March 6th. Stifel Nicolaus reduced their target price on Fate Therapeutics from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Thursday, March 6th. StockNews.com cut Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 11th. Wedbush restated a “neutral” rating and set a $5.00 target price on shares of Fate Therapeutics in a report on Thursday, March 6th. Finally, Wells Fargo & Company cut their price target on Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Fate Therapeutics presently has a consensus rating of “Hold” and an average price target of $5.50.

Fate Therapeutics Stock Performance

Shares of NASDAQ:FATE opened at $0.91 on Thursday. The company’s fifty day moving average is $1.21 and its 200-day moving average is $2.18. Fate Therapeutics has a 52 week low of $0.87 and a 52 week high of $7.65. The company has a market capitalization of $104.73 million, a PE ratio of -0.55 and a beta of 2.26.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.13. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The business had revenue of $1.86 million for the quarter, compared to analyst estimates of $1.57 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Tang Capital Management LLC lifted its holdings in Fate Therapeutics by 165.1% in the fourth quarter. Tang Capital Management LLC now owns 1,855,954 shares of the biopharmaceutical company’s stock valued at $3,062,000 after buying an additional 1,155,954 shares during the period. Walleye Capital LLC lifted its stake in shares of Fate Therapeutics by 1,502.0% in the 4th quarter. Walleye Capital LLC now owns 1,083,092 shares of the biopharmaceutical company’s stock valued at $1,787,000 after purchasing an additional 1,015,483 shares during the period. Cerity Partners LLC boosted its position in shares of Fate Therapeutics by 4,953.6% in the 4th quarter. Cerity Partners LLC now owns 823,134 shares of the biopharmaceutical company’s stock worth $1,358,000 after purchasing an additional 806,846 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Fate Therapeutics by 46.3% during the fourth quarter. Vestal Point Capital LP now owns 2,465,000 shares of the biopharmaceutical company’s stock worth $4,067,000 after purchasing an additional 780,000 shares during the period. Finally, Marshall Wace LLP bought a new stake in Fate Therapeutics in the fourth quarter valued at about $846,000. Institutional investors own 97.54% of the company’s stock.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.